Tai-huang Lee

Kaohsiung, KHQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Surgical strategy and prognostic factors in very elderly (≥ 75 Years) patients with stage I NSCLC: insights from a propensity score-matched analysis.

Surgical strategy and prognostic factors in very elderly (≥ 75 Years) patients with stage I NSCLC: insights from a propensity score-matched analysis.

Journal: BMC pulmonary medicine

Published: December 07, 2025

Clinicopathologic Predictors of Outcome and Implications for Adjuvant Therapy in Pathologic Stage II Non-small Cell Lung Cancer.

Clinicopathologic Predictors of Outcome and Implications for Adjuvant Therapy in Pathologic Stage II Non-small Cell Lung Cancer.

Journal: Anticancer research

Published: October 20, 2025

First-Line Afatinib 30 mg Versus 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in Taiwan.

First-Line Afatinib 30 mg Versus 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in Taiwan.

Journal: Anticancer research

Published: October 13, 2025

Senescent Tumoral HLA-E Reshapes Microenvironment through Impairing NK Cell-Dendritic Cell-T Cell Network in Malignant Pleural Effusion from Lung Cancer.

Senescent Tumoral HLA-E Reshapes Microenvironment through Impairing NK Cell-Dendritic Cell-T Cell Network in Malignant Pleural Effusion from Lung Cancer.

Journal: International journal of biological sciences

Published: April 26, 2025

Prognostic significance of tumor spread through air spaces and lymphovascular invasion in stage I non-small cell lung cancer: implications for adjuvant chemotherapy.

Prognostic significance of tumor spread through air spaces and lymphovascular invasion in stage I non-small cell lung cancer: implications for adjuvant chemotherapy.

Journal: World journal of surgical oncology

Published: March 23, 2025

Successful Treatment of Osimertinib Resistance in an EGFR-Mutant Lung Cancer Patient With a Rare STRN3-ALK Fusion Using Brigatinib and Osimertinib.

Successful Treatment of Osimertinib Resistance in an EGFR-Mutant Lung Cancer Patient With a Rare STRN3-ALK Fusion Using Brigatinib and Osimertinib.

Journal: The Kaohsiung journal of medical sciences

Published: February 24, 2025

CD47-mediated immune evasion in early-stage lung cancer progression.

CD47-mediated immune evasion in early-stage lung cancer progression.

Journal: Biochemical and biophysical research communications

Published: January 19, 2024

Characterization of the pleural microenvironment niche and cancer transition using single-cell RNA sequencing in EGFR-mutated lung cancer.

Characterization of the pleural microenvironment niche and cancer transition using single-cell RNA sequencing in EGFR-mutated lung cancer.

Journal: Theranostics

Published: April 07, 2023

Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib.

Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib.

Journal: Cancers

Published: January 07, 2023

Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes.

Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes.

Journal: Cancers

Published: November 21, 2022

EGFR-TKI plus antiangiogenic agent combination therapy may reduce the incidence of EGFR-TKI-associated interstitial lung disease in Asian.

EGFR-TKI plus antiangiogenic agent combination therapy may reduce the incidence of EGFR-TKI-associated interstitial lung disease in Asian.

Journal: The Kaohsiung journal of medical sciences

Published: July 07, 2022

Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis.

Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis.

Journal: Journal of clinical medicine

Published: May 19, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026